Skip to main content
TipRanks
Go Ultimate75% OFF

Investview (INVU) AI Stock Analysis

104 Followers
INVU

Investview

(Other OTC:INVU)

Select Model
Rating:38Underperform
Price Target:$0.02â–¼(-5.88% Downside)
Action:reiterated
Date:10/01/26

The overall score is very low, driven primarily by a severe deterioration in financial performance, including collapsing revenue, negative margins, and cash burn. A persistent technical downtrend and negative valuation metrics reinforce the weak outlook. The company faces significant fundamental and market-based headwinds.

Positive Factors
Subscription and Affiliate ModelSubscription access and an affiliate-style distribution network provide a repeatable commercial framework for selling education, analytical tools, and related services. Recurring memberships can support customer continuity, while representatives extend distribution without requiring a fully company-owned sales force.
Negative Factors
Revenue and Profitability DeteriorationThe latest annual results show weakening demand or execution alongside a sharp earnings reversal, moving from modest profitability in 2024 to a sizable loss. Persistent revenue contraction would reduce operating scale, while the negative margin limits internally funded investment and recovery capacity.

Investview (INVU) vs. SPDR S&P 500 ETF (SPY)

-60%-40%-20%0%20%INVU-41.38%SPY+14.97%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$32.28M
Dividend Yield
―
Average Volume (3M)
689.23K
Price to Earnings (P/E)
-1.9
Beta (1Y)
-0.28
Revenue Growth
-48.30%
EPS Growth
-718.18%
Country
US
Employees
42
Sector
Technology
Sector Strength
61
Industry
Software - Application

Investview Business Overview & Revenue Model

Company Description

Investview, Inc., operating through its various subsidiaries, offers a comprehensive suite of financial literacy resources, digital asset solutions, and supporting technology platforms primarily for individual users. The firm provides services includ...

How the Company Makes Money

Investview primarily makes money through (1) subscription and membership fees for access to its financial education content, analytical tools, and related services sold to customers and distributed via an independent representative/affiliate network;...

Investview Financial Statement Overview

Summary

Financial performance is critically weak. Revenue has collapsed from $89.3M to $36.3M, gross profit fell to zero, and the company posted a net loss of $8.9M. Operating and free cash flow are both negative, indicating severe instability and an inability to self-fund.

Income Statement

20Very Negative

Balance Sheet

40Negative

Cash Flow

25Negative
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2023Dec 2021Mar 2021
Income Statement
Total Revenue22.57M36.26M52.38M61.85M89.29M24.18M
Gross Profit8.79M20.23M39.70M53.60M75.14M21.68M
EBITDA-10.83M-8.26M7.22M12.18M-19.90M-6.68M
Net Income-15.76M-8.91M1.19M-12.94M-24.97M-21.29M
Balance Sheet
Total Assets13.48M21.50M31.57M35.58M51.50M10.40M
Cash, Cash Equivalents and Short-Term Investments1.99M9.99M23.60M20.47M31.00M137.18K
Total Debt1.22M1.28M3.44M10.72M14.02M3.79M
Total Liabilities6.44M12.57M14.37M18.20M22.56M24.66M
Stockholders Equity1.59M8.92M17.19M17.37M-72.92M-14.26M
Cash Flow
Free Cash Flow7.04M-3.70M7.84M-5.91M30.34M-620.84K
Operating Cash Flow11.36M-3.70M8.30M9.36M32.98M4.62M
Investing Cash Flow-5.73M-4.21M-1.60M-14.17M-2.63M-5.25M
Financing Cash Flow-2.87M-4.57M-5.37M-6.31M711.91K624.37K

Investview Technical Analysis

Technical Analysis SentimentNeutral
Last Price0.02

Price Trends

50DMA0.02Positive
100DMA0.02Negative
200DMA0.02Negative

Market Momentum

MACD0.00Positive
RSI54.68Neutral
STOCH145.24Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INVU, the sentiment is Neutral. The current price of 0.02 is below the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.02, and below the 200-day MA of 0.02, indicating a neutral trend. The MACD of 0.00 indicates Positive momentum. The RSI at 54.68 is Neutral, neither overbought nor oversold. The STOCH value of 145.24 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for INVU.

Investview Risk Analysis

Investview disclosed 57 risk factors in its most recent earnings report. Investview reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.Our business remains heavily impacted by interested party transactions with certain of our officers and directors.Q4, 2023
2.Conversion of exchangeable shares issued in connection with the acquisition of the assets of MPower.Q4, 2023
3.Even though we were profitable for the year ended December 31, 2023, we have a history of losses from operations.Q4, 2023

Investview Peers Comparison

Overall Rating

UnderperformOutperform
Sector (61)

Financial Indicators

INVU against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
NTWKNTWK70Outperform$82.35M11.9815.45%―13.94%1032.68%
Sector *61Neutral$37.18B12.37-10.20%1.83%8.50%-7.62%
INLXINLX47Neutral$17.40M-5.92-26.38%―-5.53%-56.77%
AWREAWRE44Neutral$20.84M-2.46-36.87%―-9.81%-45.08%
PHUNPHUN44Neutral$36.60M-2.68-13.83%―14.63%11.10%
SURGSURG44Neutral$9.30M-0.09193.81%―83.91%38.02%
INVUINVU38Underperform$31.62M-1.92-194.91%―-48.30%-718.18%

* Technology Sector Average

Performance Comparison

0%100%INVUAWRENTWKPHUNINLXSURGDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
INVU and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
INVUInvestview Inc.0.02-0.01-41.38%
AWREAware Inc.0.94-1.29-58.07%
NTWKNetsol5.292.4384.79%
PHUNPhunware1.74-0.32-15.53%
INLXIntellinetics, Inc.3.74-5.30-58.63%
SURGSurgepays Inc0.14-1.76-92.63%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 01, 2026